Vericel Corporation is a biopharmaceutical company developing cellular therapies for sports medicine and severe burn care markets in North America. Products include MACI for knee cartilage repair, Epicel for skin replacement, and NexoBrid for eschar removal in thermal burns.
| Indicator | Value |
|---|---|
| PER | 106.4 |
| EV/EBITDA | 59.4 |
| Price/Free Cash Flow' | 71.0 |
| ROIC | 11.5% |
| Net Debt/EBITDA | 100.0 |